Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack
复制标题
DOI：
10.1161/strokeaha.107.189063
复制
发表时间：
2008-05-01
期刊：
影响因子：
8.3
通讯作者：
Schwamm, Lee H.
中科院分区：
文献类型：
--
作者：
Adams, Robert J.;Albers, Greg;Schwamm, Lee H.
分析，这是受两个类型I和类型II的错误，应谨慎解释。在索引事件发生后5年内开始研究药物治疗显著超过卒中复发的高风险期。目前，在高危患者中使用氯吡格雷治疗动脉粥样硬化血栓形成（MATCH）研究仍然是这些治疗在脑血管疾病患者中更相关的试验。CHARISMA试验显示，在有缺血性卒中病史的患者中，阿司匹林和氯吡格雷联合使用对预防卒中没有益处。氯吡格雷和阿司匹林的联合治疗适用于近期发生冠状动脉事件和/或既往接受过血管支架植入术的患者，但是，关于阿司匹林和氯吡格雷用于冠状动脉适应症的信息，请读者参考最新的美国心脏病学会/AHA指南。
analyses, which are subject to both type I and type II error, should be interpreted cautiously. Initiation of study drug up to 5 years after the index event is significantly beyond the high-risk period for stroke recurrence. At this time, the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) study remains a more relevant trial of these therapies in patients with cerebrovascular disease. 3 The CHARISMA trial showed no benefit for combined use of aspirin and clopidogrel for stroke prevention in patients with prior history of ischemic stroke. Limited-duration combination clopidogrel and aspirin therapy is indicated in patients with recent coronary events and/or prior vascular stenting, however, and the reader is referred to the latest American College of Cardiology/AHA guidelines for information on aspirin and clopidogrel for coronary indications.